Detection of synthetic cannabinoid adulteration in the unregulated drug supply in three Canadian settings
Abstract
Background: Novel psychoactive substances (NPS) are increasingly being consumed worldwide, with synthetic cannabinoids and synthetic opioids being the second and third most commonly used NPS, respectively. Certain synthetic cannabinoids can produce significant harms, particularly when used with opioids. The objective of this study was to characterise the presence of synthetic cannabinoids in the unregulated drug supply in three Canadian settings
Methods: In the British Columbia setting, all samples were first analysed at point‐of‐care using combination Fourier‐transform infrared (FTIR) spectroscopy and fentanyl immunoassay strips prior to confirmatory testing using quantitative nuclear magnetic resonance spectroscopy, gas chromatography/mass spectrometry (GC/MS) and/or liquid chromatography/mass spectrometry (LC/MS). In the Toronto, Ontario setting, the samples were analysed directly by GC/MS, LC/MS liquid chromatography‐high resolution/mass spectrometry.
Results: Between January 2018 and December 2019, 38 (2.8%) synthetic cannabinoid samples were detected in the unregulated drug supply (25/909 in British Columbia and 13/440 in Ontario). In British Columbia and Ontario, 76% and 85% of samples, respectively, were expected by individuals to be an opioid. Synthetic cannabinoids detected included AMB‐FUBINACA, AB‐FUBINACA, 5‐fluoro‐MDMB‐PINACA, and 5‐fluoro‐MDMB‐PICA, and largely co‐occurred with fentanyl. In the British Columbia context, Fourier‐transform infrared spectroscopy failed to detect synthetic cannabinoid compounds in almost half (48%) of the samples at point‐of‐care.
Conclusion: As point‐of‐care technologies failed to detect these compounds in many occasions, our findings demonstrate the importance of laboratory confirmatory analysis to identify NPS. Given the high risk of harm associated with the consumption of synthetic cannabinoids, further research should investigate the reasons for adulteration.
View full article here.
Related Content
Piloting and evaluating drug checking services in Toronto, Ontario
The pilot for Toronto’s Drug Checking Service, which checked and publicly reported on more than 10,000 samples between October 10, 2019, and June 30, 2023, was coordinated by the CDPE. While Toronto’s Drug Checking Service now operates from its own unit within MAP Centre for Urban Health Solutions at St. Michael’s Hospital, a site of Unity Health Toronto, the CDPE continues to work collaboratively with and conduct scientific research on the program.
View
Toronto's Drug Checking Service Website
Toronto's drug checking service has launched an interactive website! We will now publicly share regular information on Toronto’s unregulated drug supply, supporting more evidence-based harm reduction practices, policy, research, and care for people who use drugs.
View
Drug checking use and interest among people who inject drugs in Toronto, Canada
Drug checking services (DCS) provide information on drug composition to inform consumption practices and monitor unregulated drug markets. We sought to identify correlates of recent informal DCS use (e.g., fentanyl test strips) and willingness to use a formal DCS (co-located within a supervised consumption site and employing laboratory-based analyses) in Toronto, Canada prior to its implementation.
View
Emerging synthetic cannabinoids detected by a drug checking service in Toronto, Canada
This article reports on new synthetic cannabinoids (SCs) detected in drug samples submitted to Toronto’s Drug Checking Service (DCS) in Toronto, Canada, in the period following restrictions related to the COVID-19 pandemic in Ontario, during which global drug trafficking patterns are believed to have been affected.
View
Diverse psychotropic substances detected in drug and drug administration equipment samples submitted to drug checking services in Toronto, Ontario, Canada, October 2019–April 2020
This report presents early trends of samples analyzed within the first six months of drug checking service implementation in Toronto, Ontario. We sought to identify the prevalence of high-potency opioids in the unregulated drug supply and to identify noteworthy combinations thereof with stimulants, benzodiazepine-type drugs, and synthetic cannabinoids. We also present data on reported negative effects of samples (e.g., overdose).
View
Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications
We report the first detection of the psychoactive veterinary compound xylazine in Toronto, the largest urban center in Canada, by the city’s drug checking service.
View
What’s in Toronto’s drug supply? Results from samples checked by Toronto’s drug checking service: January 1 – December 31, 2020
Between January 1 and December 31, 2020, 1657 samples were checked using mass spectrometry technologies (gas- and liquid-chromatography). This report details the results from the analysis of those samples.
View
Evaluating Networked Drug Checking Services in Toronto, Ontario: Study Protocol and Rationale
As a harm reduction intervention available in Europe since the 1990s, DCS provide information on the composition of drugs to their clients in order to facilitate more informed drug-related decision-making and to increase the capacity of individuals to avoid ingesting unanticipated toxic substances, which can lead to overdose and death.
View
What’s in Toronto’s Drug Supply?
Results from samples checked by Toronto's drug checking service between October 10, 2019 - March 31, 2020.
View
Drug Checking Services for People Who Use Drugs: A Systematic Review
Given the growing availability of drug checking services and interest in their impacts, we conducted a systematic review to investigate the (a) influence of drug checking services on behaviour of people who use drugs, (b) monitoring of drug markets by drug checking services, and (c) outcomes related to models of drug checking services.
View